Neurometrix Inc (NASDAQ:NURO) Given $5.00 Consensus Price Target by Analysts

Shares of Neurometrix Inc (NASDAQ:NURO) have received an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.

Brokers have set a twelve-month consensus price objective of $5.00 for the company and are expecting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Neurometrix an industry rank of 67 out of 256 based on the ratings given to related companies.

Several research analysts have recently weighed in on the company. ValuEngine raised Neurometrix from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Zacks Investment Research lowered Neurometrix from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Neurometrix in a report on Friday, April 26th.

Shares of Neurometrix stock traded up $0.01 during trading on Tuesday, reaching $0.37. 17,600 shares of the company were exchanged, compared to its average volume of 151,534. Neurometrix has a twelve month low of $0.35 and a twelve month high of $1.40. The business’s 50-day simple moving average is $0.43.

Neurometrix (NASDAQ:NURO) last posted its earnings results on Thursday, July 18th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. Neurometrix had a negative return on equity of 17.31% and a negative net margin of 23.52%. The firm had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $3.28 million. As a group, research analysts predict that Neurometrix will post -0.35 earnings per share for the current fiscal year.

Neurometrix Company Profile

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Read More: What is Cost of Debt?

Get a free copy of the Zacks research report on Neurometrix (NURO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.